Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EBIT: 2019-2024

Historic EBIT for Praxis Precision Medicines (PRAX) over the last 6 years, with Dec 2024 value amounting to -$200.2 million.

  • Praxis Precision Medicines' EBIT fell 37.87% to -$78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$293.1 million, marking a year-over-year decrease of 78.71%. This contributed to the annual value of -$200.2 million for FY2024, which is 58.39% down from last year.
  • As of FY2024, Praxis Precision Medicines' EBIT stood at -$200.2 million, which was down 58.39% from -$126.4 million recorded in FY2023.
  • Over the past 5 years, Praxis Precision Medicines' EBIT peaked at -$62.0 million during FY2020, and registered a low of -$215.0 million during FY2022.
  • Moreover, its 3-year median value for EBIT was -$200.2 million (2024), whereas its average is -$180.5 million.
  • Its EBIT has fluctuated over the past 5 years, first slumped by 170.03% in 2021, then soared by 41.22% in 2023.
  • Over the past 5 years, Praxis Precision Medicines' EBIT (Yearly) stood at -$62.0 million in 2020, then slumped by 170.03% to -$167.3 million in 2021, then fell by 28.48% to -$215.0 million in 2022, then surged by 41.22% to -$126.4 million in 2023, then tumbled by 58.39% to -$200.2 million in 2024.